1887

oa SA Pharmaceutical Journal - New product focus : drug info

 

Abstract


Rivaroxaban (Xarelto®) is a new oral anticoagulant that was recently registered in South Africa. It is the first of two new orally administered anticoagulants poised to change anticoagulation practices by offering improvements over the current standard of care, such as fixed oral dosing and no need for routine monitoring.

Loading

Article metrics loading...

/content/mp_sapj/77/4/EJC82371
2010-05-01
2016-12-03
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error